Verified Clinical Benefit – non-malignant hematological, neurological and other disorder indications (Provayblue row) (2026)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research · November 19, 2026

U.S. Food et al., 2026-11-19: FDA's accelerated-approval tracking table lists Provayblue (methylene blue) for pediatric and adult acquired methemoglobinemia with an accelerated approval date of 8 April 2016 and a traditional (full) approval date of 8 January 2024.

Provayblue (methylene blue) For the treatment of pediatric and adult patients with acquired methemoglobinemia 4/8/2016 1/8/2024

U.S. Food et al., 2026-11-19: FDA's accelerated-approval tracking table lists Provayblue (methylene blue) for pediatric and adult acquired methemoglobinemia with an accelerated approval date of 8 April 2016 and a traditional (full) approval date of 8 January 2024. Study type: regulatory record.